{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"825","value":"0.0471"},{"groupId":"OG001","spread":"223","value":"0.892"},{"groupId":"OG002","spread":"140","value":"4.12"},{"groupId":"OG003","spread":"44","value":"24.7"},{"groupId":"OG004","spread":"66","value":"46.7"},{"groupId":"OG005","spread":"42","value":"113"},{"groupId":"OG006","spread":"31","value":"0.0227"},{"groupId":"OG007","spread":"248","value":"0.792"},{"groupId":"OG008","spread":"269","value":"1.11"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"107"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"13"}],"units":"Participants"}],"title":"IMGN632 ADC: Cycle 1"},{"categories":[{"measurements":[{"comment":"Geometric Coefficient of Variation not calculable with n=1","groupId":"OG000","spread":"NA","value":"0.152"},{"groupId":"OG001","spread":"241","value":"0.939"},{"groupId":"OG002","spread":"254","value":"3.50"},{"groupId":"OG003","spread":"66","value":"31.0"},{"groupId":"OG004","spread":"68","value":"51.8"},{"groupId":"OG005","spread":"50","value":"123"},{"groupId":"OG007","spread":"355","value":"0.708"},{"groupId":"OG008","spread":"371","value":"1.02"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"94"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"12"}],"units":"Participants"}],"title":"Total Antibody: Cycle 1"},{"categories":[{"measurements":[{"comment":"Geometric Coefficient of Variation not calculable with n=1","groupId":"OG000","spread":"NA","value":"0.202"},{"groupId":"OG001","spread":"191","value":"1.61"},{"groupId":"OG002","spread":"56","value":"12.1"},{"groupId":"OG006","spread":"1831","value":"0.0145"},{"groupId":"OG007","spread":"185","value":"1.25"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"0"}],"units":"Participants"}],"title":"IMGN632 ADC: Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"124","value":"1.41"},{"groupId":"OG002","spread":"111","value":"15.4"},{"comment":"Geometric Coefficient of Variation not calculable with n=1","groupId":"OG006","spread":"NA","value":"0.0835"},{"groupId":"OG007","spread":"121","value":"1.05"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"66"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"0"}],"units":"Participants"}],"title":"Total Antibody: Cycle 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"107"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"13"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received IMGN632 at a dose of 0.015 mg/kg via IV infusion on Day 1 of each 21-day cycle.","id":"OG000","title":"Schedule A: IMGN632 0.015 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.045 mg/kg via IV infusion on Day 1 of each 21-day cycle.","id":"OG001","title":"Schedule A: IMGN632 0.045 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.09 mg/kg via IV infusion on Day 1 of each 21-day cycle.","id":"OG002","title":"Schedule A: IMGN632 0.09 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.18 mg/kg via IV infusion on Day 1 of each 21-day cycle.","id":"OG003","title":"Schedule A: IMGN632 0.18 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.3 mg/kg via IV infusion on Day 1 of each 21-day cycle.","id":"OG004","title":"Schedule A: IMGN632 0.3 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.45 mg/kg via IV infusion on Day 1 of each 21-day cycle.","id":"OG005","title":"Schedule A: IMGN632 0.45 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.015 mg/kg via IV infusion on Days 1, 4, and 8 of each 21-day cycle.","id":"OG006","title":"Schedule B: IMGN632 0.015 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.03 mg/kg via IV infusion on Days 1, 4, and 8 of each 21-day cycle.","id":"OG007","title":"Schedule B: IMGN632 0.03 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.06 mg/kg via IV infusion on Days 1, 4, and 8 of each 21-day cycle.","id":"OG008","title":"Schedule B: IMGN632 0.06 mg/kg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK analysis set included all participants who received at least 1 dose of study drug and from whom results of concentration had been obtained at least 1 sampling point. PK data were collected and analyses were conducted in participants per treatment schedule and dose in both phases (dose escalation and expansion) combined. Here, 'number analyzed' = participants evaluable for specified categories.","reportingStatus":"POSTED","timeFrame":"Cycle 1 and Cycle 3 (each cycle length = 21 days)","title":"Area Under the Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last) of IMGN632 (ADC) and Total Antibody","type":"SECONDARY","unitOfMeasure":"hours*µg/mL"}